Journal ArticleDOI
External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients
David J. Rosenberg,Anne Press,Joanna Fishbein,Martin Lesser,Lauren McCullagh,Thomas McGinn,Alex C. Spyropoulos +6 more
TLDR
This study represents the largest externally validated Bleed RAM in a hospitalised medically ill patient population and a cut-off point score of 7 or above was able to identify a high-risk patient group for MB and any bleed.Abstract:
The IMPROVE Bleed Risk Assessment Model (RAM) remains the only bleed RAM in hospitalised medical patients using 11 clinical and laboratory factors. The aim of our study was to externally validate the IMPROVE Bleed RAM. A retrospective chart review was conducted between October 1, 2012 and July 31, 2014. We applied the point scoring system to compute risk scores for each patient in the validation sample. We then dichotomised the patients into those with a scoreread more
Citations
More filters
Journal ArticleDOI
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
Holger J. Schünemann,Mary Cushman,Allison Burnett,Susan R. Kahn,Jan Beyer-Westendorf,Frederick A. Spencer,Suely M. Rezende,Neil A. Zakai,Kenneth A. Bauer,Francesco Dentali,Jill Lansing,Sara Balduzzi,Andrea Darzi,Gian Paolo Morgano,Ignacio Neumann,Ignacio Neumann,Robby Nieuwlaat,Juan José Yepes-Nuñez,Yuan Zhang,Wojtek Wiercioch +19 more
TL;DR: These evidence-based guidelines from the American Society of Hematology intend to support patients, clinicians, and others in decisions about preventing VTE in medical inpatients and outpatients with minor injuries and long-distance travelers.
Journal ArticleDOI
New paradigms in venous thromboprophylaxis of medically ill patients
TL;DR: Current concepts of VTE and bleed risk in hospitalised medical patients, both in the hospital as well as the post-hospital discharge period are reviewed, and new paradigms of thromboprophylaxis in this population are discussed using an individualised, patient-centered approach.
Journal ArticleDOI
Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system.
TL;DR: A task force was assembled to address the utilization of anti-thrombotic and anti-platelet therapy in COVID-19 positive or suspected patients, and current guidelines, consensus documents, and policy documents from specialty organizations were used to formulate health system recommendations.
Journal ArticleDOI
AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.
Robert S. O’Shea,Perica Davitkov,Cynthia W. Ko,Anita Rajasekhar,Grace L. Su,Shahnaz Sultan,Alina M. Allen,Yngve Falck-Ytter +7 more
Journal ArticleDOI
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.
Pablo Olivera,Stéphane Zuily,Paulo Gustavo Kotze,Véronique Regnault,Sameer Al Awadhi,Peter Bossuyt,Richard B. Gearry,Subrata Ghosh,Taku Kobayashi,Patrick Lacolley,Edouard Louis,Fernando Magro,Siew C. Ng,Alfredo Papa,Alfredo Papa,Tim Raine,Fábio Vieira Teixeira,David T. Rubin,Silvio Danese,Laurent Peyrin-Biroulet +19 more
TL;DR: The evidence-based guideline as mentioned in this paper summarizes available evidence and provides practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with inflammatory bowel disease.
References
More filters
Journal ArticleDOI
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Clive Kearon,Elie A. Akl,Anthony J. Comerota,Paolo Prandoni,Henri Bounameaux,Samuel Z. Goldhaber,Michael E. Nelson,Philip S. Wells,Michael K. Gould,Francesco Dentali,Mark Crowther,Susan R. Kahn +11 more
TL;DR: Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.
Journal ArticleDOI
Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Yngve Falck-Ytter,Charles W. Francis,Norman A. Johanson,Catherine Curley,Ola E. Dahl,Sam Schulman,Thomas L. Ortel,Stephen G. Pauker,Clifford W. Colwell +8 more
TL;DR: In this article, the authors focus on optimal prophylaxis to reduce postoperative pulmonary embolism and DVT following major orthopedic surgery, and suggest the use of low-molecular-weight heparin in preference to the other agents we have recommended as alternatives.
Journal ArticleDOI
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Meyer Michel Samama,Alexander T. Cohen,Jean-Yves Darmon,Louis Desjardins,Amiram Eldor,Charles Janbon,Alain Leizorovicz,Hélène Nguyen,Carl-Gustav Olsson,Alexander Graham Turpie,Nadine Weisslinger +10 more
TL;DR: Prophylactic treatment with 40 mg of enoxaparin subcutaneously per day safely and effectively reduces the risk of venous thromboembolism in patients with acute medical illnesses.
Journal ArticleDOI
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.
Alexander T. Cohen,Victor F. Tapson,Jean-François Bergmann,Samuel Z. Goldhaber,Ajay K. Kakkar,Bruno Deslandes,Wei Huang,Maksim Zayaruzny,Leigh A. Emery,Frederick A. Anderson +9 more
TL;DR: A large proportion of hospitalised patients are at risk for VTE, but there is a low rate of appropriate prophylaxis, which reinforces the rationale for the use of hospital-wide strategies to assess patients' VTE risk and to implement measures that ensure that at-risk patients receive appropriate proPHylaxis.
Journal ArticleDOI
Venous thromboembolism (VTE) in Europe - The number of VTE events and associated morbidity and mortality
Alexander T. Cohen,Giancarlo Agnelli,Frederick A. Anderson,Juan I. Arcelus,David Bergqvist,Josef G. Brecht,Ian A. Greer,John A. Heit,Julia L. Hutchinson,Ajay K. Kakkar,Dominique Mottier,Emmanuel Oger,Meyer Michel Samama,Michael Spannagl +13 more
TL;DR: The estimated total number of symptomatic VTE events (range based on probabilistic sensitivity analysis) per annum within the six EU countries was 465,715; almost three-quarters of all VTE-related deaths were from hospital-acquired VTE.